Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: Effects on insulin-like growth factor II

Cancer

Volumn 95, Issue 8, 2002, Pages 1735-1745

  Braczkowski, Ryszard ^a,b,c   Schally, Andrew V ^a,b   Plonowski, Artur ^a,b   Varga, Jozsef L ^a,b   Groot, Kate ^a   Krupa, Magdalena ^a,b   Armatis, Patricia ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Ewing sarcoma; Growth hormone releasing hormone antagonists; Insulin like growth factor I; Insulin like growth factor II; Osteosarcoma

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; JV 1 18; JV I 38; MESSENGER RNA; SOMATOMEDIN B; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; EWING SARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; NUDE MOUSE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALS; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE-RELEASING HORMONE; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; MICE, NUDE; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA, EWING'S; TUMOR CELLS, CULTURED;

EID: 0037108564     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10865     Document Type: Article

References (45)

1. Dorfmann HD, Czerniak B. Bone cancers. Cancer. 1995;75: 203-210.
2. Whelan JS. Osteosarcoma. Eur J Cancer. 1997;33:1611-1119.
3. Jaffe N, Patel SR, Benjamin RS. Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation. Early controversies surrounding its implementation. Hematol Oncol Clin North Am. 1995;9:825-840.
4. Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with nonmetastatic osteosarcoma of the extremity, treated with neoadjuvant chemotherapy. Ann Oncol. 1997;8:765-771.
5. Saeter G, Høie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim ØP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer. 1995;75:1084-1093.
6. Rosen G. Bone Tumors. In: Holland IK, Frei E III, Bast RC Jr., Kufe DE, Morton DL, Weichselbaum RR, editors. Cancer medicine, 3rd ed, vol 2. Philadelphia: Lea & Febiger, 1993: 1825-1884.
7. Blatt J, White C, Dienes S, Friedman H, Foley TP Jr. Production of an insulin like growth factor by osteosarcoma. Biochem Biophys Res Commun. 1984;123:373-376.
8. Pollak MN, Polychronakos C, Richard M. Insulin-like growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst. 1990;82:301-305.
9. Pollak MN, Sem AW, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst. 1992;84:966-971.
10. Scheven BA, Hamilton NJ, Fakkeldij TM, Duursma SA. Effects of recombinant human insulin-like growth factor I and II (IGF-I/IGF-II) and growth hormone (GH) on the growth of normal adult human osteoblast like-cells and human osteogenic sarcoma cells. Growth Regul. 1991;1:160-167.
11. Schally AV. Oncological applications of somatostatin analogs. Cancer Res. 1988;48:6977-69785.
12. Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasm potentially dependent on IGF-I. Anticancer Res. 1989;9:889-891.
13. Zarandi M, Horvath JE, Halmos G, et al. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA. 1994; 91:12298-12302.
14. Varga JL, Schally AV, Csernus VJ, et al. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci USA. 1999;96:692-697.
15. Schally AV, Varga JL. Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends Endocrinol Metab. 1999;10:383-391.
16. Pinski J, Schally AV, Groot K, et al. Inhibition of growth of human osteosarcomas by antagonists of growth hormonereleasing hormone. J Natl Cancer Inst. 1995;87:1787-1794.
17. Schally AV, Comaru-Schally AM, Nagy A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol Invited Rev. 2001;22:248-291.
18. Csernus VJ, Schally AV, Kiaris H, Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone releasing hormone in vitro. Proc Natl Acad Sci USA. 1999;96:3098-3103.
19. Kahan Z, Varga JL, Schally AV, et al. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen independent human breast cancers in nude mice. Breast Cancer Res Treat. 2000;60:71-79.
20. Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumors. Eur J Cancer. 2000;36:128-136.
21. Plonowski A, Schally AV, Varga JL, et al. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists, indicative of interference with both IGF and EGF pathways. Prostate. 2000;44:172-180.
22. Szepeshazi K, Schally AV, Groot K, et al. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer. 2000;82:1724-1731.
23. Chatzistamou I, Schally AV, Varga JL, et al. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J Clin Endocrinol Metab. 2001;86:2144-2152.
24. Lamharzi N, Schally AV, Koppan M, Groot K. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor-II in tumors. Proc Natl Acad Sci USA. 1998;95:8864-8868.
25. Kiaris H, Schally AV, Varga JL. Antagonists of growth hormone releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia. 2000;2:242-250.
26. Toretsky JA, Helman LJ. Involvement of IGF-II in human cancer. J Endocrinol. 1996;149:367-372.
27. Daughaday WH. The possible autocrine/paracrine end endocrine roles of insulin like growth factors of human tumors. Endocrinology. 1990;127:1-4.
28. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Rev. 2000;21:215-244.
29. Fournier B, Ferralli JM, Price PA, Schlaeppi JM. Comparison of the effects of insulin-like growth factors-I and -II on the human osteosarcoma cell line OHS-4. J Endocrinol. 1993; 136:173-180.
30. Raile K, Hoflich A, Kessler U, et al. Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor (IGF)-I receptors and insulin-like growth factor II/mannose-6-phosphate (IGF-II/M6P receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol. 1994,159:531-541.
31. Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin like growth factor receptor, IGF-I and IGF-II in primary and metastatic osteosarcoma. J Surg Oncol. 1998;69: 21-27.
32. Rhim JS, Park DK, Arnstein P, Huebner RJ, Weisburger EK, Nelson-Rees WA. Transformation of human cells in culture by N-methyl-N′-nitro-N-nitrosoguanidine. Nature. 1975;256:751-753.
33. Bloom ET. Further definition by cytotoxicity tests of cell surface antigens of human sarcomas in culture. Cancer Res. 1972;32:960-967.
34. Breier BH, Gallaher BW, Gluckman PD. Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. J Endocrinol. 1991;128:347-357.
35. Daughaday WH, Mariz IK, Blethen SL. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanolextracted serum. J Clin Endocrinol Metab. 1980;51:781-788.
36. Tanaka H, Asami O, Hayano T, Sasaki I, Yoshitake Y, Nishikawa K. Identification of a family of insulin-like growth factor II secreted by cultured rat epithelial-like cell line 18,54-SF: application of a monoclonal antibody. Endocrinology. 1989;124:870-877.
37. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev. 1995;16: 3-34.
38. Vermeulen A. Nyctohumoral growth hormone profiles in young and aged man: correlations with somatomedin-C levels. J Clin Endocrinol Metab. 1987;64:884-888.
39. Gangji V, Rydziel S, Gabbitas B, Canalis E. Insulin-like growth factor II promoter expression in cultured rodent osteoblasts and adult rat bone. Endocrinology. 1998;139: 2287-2292.
40. Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res. 1995;55:129-134.
41. Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci USA. 2000;97:10555-10560.
42. Rekasi Z, Czompoly T, Schally AV, Halmos G. Isolation and sequencing of cDNAs for splice variants of growth hormonereleasing hormone receptors from human cancers. Proc Natl Acad Sci USA. 2000;97:10561-10566.
43. Kiaris H, Schally AV, Varga JL. Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma. Cancer Lett. 2000;161:149-155.
44. Chatzistamou I, Schally AV, Varga JL, et al. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs. 2001;12:761-768.
45. Busto R, Schally AV, Braczkowski R, et al. Expression of mRNA for growth hormone-releasing hormone (GH-RH), and splice variants of GH-RH receptors in human osteosarcomas. Regul Peptides. In press.